Department of Clinical Research Management, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, China.
Chin Med J (Engl). 2024 Nov 5;137(21):2577-2582. doi: 10.1097/CM9.0000000000003268. Epub 2024 Sep 24.
Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases and deaths due to lung cancer in China and the United States in 2050.
In this study, data from the GLOBCAN 2022 database were used to analyze lung cancer incidence and mortality. The current status of lung cancer incidence and deaths was described by country/region, sex, age, and the human development index (HDI), and future lung cancer incidence and deaths in China and the United States were projected for 2050.
Globally, an estimated 2,480,675 new lung cancer cases and 1,817,469 lung cancer-related deaths occurred in 2022, with age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) of 23.6/100,000 and 16.8/100,000, respectively. In China, the ASIR and ASMR for male lung cancer patients were approximately 1.7 times and 2.7 times greater than those for female lung cancer patients, respectively. The ASIR and ASMR in high-HDI countries were approximately 8.5 times and 6.5 times those in low-HDI countries, respectively. It is estimated that in 2050, there will be approximately 1120 thousand new cases and 960 thousand deaths among Chinese men, 680 thousand new cases and 450 thousand deaths among Chinese women, approximately 170 thousand new cases and 110 thousand deaths among American men, and 160 thousand new cases and 90 thousand deaths among American women.
There are significant differences in the incidence and mortality of lung cancer among different regions and sexes. Therefore, sex factors need to be considered in the prevention, screening, and treatment strategies of lung cancer, and the implementation of tertiary prevention measures for lung cancer, especially primary and secondary prevention, needs to be actively promoted.
肺癌是最常见的癌症，也是全球癌症相关死亡的主要原因。本研究旨在评估 2022 年全球肺癌的发病率和死亡率，并预测 2050 年中国和美国肺癌新发病例和死亡人数。
本研究使用 GLOBCAN 2022 数据库中的数据来分析肺癌的发病率和死亡率。通过国家/地区、性别、年龄和人类发展指数（HDI）描述当前肺癌发病率和死亡率的现状，并预测 2050 年中国和美国的未来肺癌发病率和死亡率。
全球 2022 年估计有 248.0675 例新肺癌病例和 181.7469 例肺癌相关死亡，年龄标准化发病率（ASIR）和年龄标准化死亡率（ASMR）分别为 23.6/100000 和 16.8/100000。在中国，男性肺癌患者的 ASIR 和 ASMR 分别约为女性的 1.7 倍和 2.7 倍。高 HDI 国家的 ASIR 和 ASMR 分别约为低 HDI 国家的 8.5 倍和 6.5 倍。预计 2050 年中国男性将有约 112 万例新发病例和 96 万例死亡，中国女性将有约 68 万例新发病例和 45 万例死亡，美国男性将有约 17 万例新发病例和 11 万例死亡，美国女性将有约 16 万例新发病例和 9 万例死亡。
不同地区和性别的肺癌发病率和死亡率存在显著差异。因此，在制定肺癌的预防、筛查和治疗策略时，需要考虑性别因素，并积极推行肺癌三级预防措施，特别是一级和二级预防。
